Agenus Inc (NASDAQ:AGEN) VP Christine M. Klaskin sold 5,610 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $3.46, for a total value of $19,410.60. Following the completion of the sale, the vice president now directly owns 69,943 shares of the company’s stock, valued at $242,002.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Agenus Inc (NASDAQ AGEN) traded up $0.04 during midday trading on Friday, hitting $3.56. The company had a trading volume of 789,242 shares, compared to its average volume of 1,070,000. The company has a debt-to-equity ratio of -2.39, a current ratio of 1.55 and a quick ratio of 1.55. Agenus Inc has a 52-week low of $3.20 and a 52-week high of $5.45.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.37). The company had revenue of $3.40 million for the quarter, compared to analyst estimates of $5.91 million. The firm’s revenue was down 24.4% compared to the same quarter last year. sell-side analysts predict that Agenus Inc will post -1.19 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Agenus by 5.2% during the second quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock worth $13,805,000 after purchasing an additional 174,162 shares during the period. Artal Group S.A. lifted its holdings in shares of Agenus by 25.0% during the third quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock worth $11,025,000 after purchasing an additional 500,000 shares during the period. Northern Trust Corp lifted its holdings in shares of Agenus by 4.1% during the second quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock worth $3,682,000 after purchasing an additional 37,239 shares during the period. Candriam Luxembourg S.C.A. lifted its holdings in shares of Agenus by 12.8% during the third quarter. Candriam Luxembourg S.C.A. now owns 617,700 shares of the biotechnology company’s stock worth $2,724,000 after purchasing an additional 70,000 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Agenus by 5.8% during the first quarter. Geode Capital Management LLC now owns 554,572 shares of the biotechnology company’s stock worth $2,090,000 after purchasing an additional 30,265 shares during the period. 37.90% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Wednesday, October 25th. BidaskClub downgraded Agenus from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Finally, ValuEngine raised Agenus from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $5.81.

WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/12/16/christine-m-klaskin-sells-5610-shares-of-agenus-inc-agen-stock.html.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.